Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...
On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...
On Saturday, Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in patients with sickle cell disease (SCD) with severe ...
Beam Therapeutics has announced significant progress in its clinical trials and portfolio regarding precision genetic medicines, particularly in the area of sickle cell disease (SCD). Over 40 adult ...
Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients. Beam Therapeutics Inc. has announced that it will present updated ...
CAMBRIDGE, Mass. - Beam Therapeutics Inc. (NASDAQ:BEAM), a $1.7 billion market cap biotechnology company currently trading near $17.44, reported updated data from 17 patients in its BEACON Phase 1/2 ...
StoreDot has unveiled what it is calling a ‘breakthrough concept’ for taking extreme fast charging (XFC) capability from the cell to the vehicle level with its new I-BEAM XFCTM concept. An innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback